China Diabetes Therapeutics Market Report 2022 to 2030

China Diabetes Therapeutics Market Analysis

$ 3999

China's diabetes therapeutics market is expected to grow from $11.56 Bn in 2022 to $27.04 Bn in 2030 with a CAGR of 11.2% for the forecasted year 2022-2030. The rise in the ageing population of China and the introduction of novel therapeutic options in China are the major growth drivers of the market. The China diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel. Yunnan Baiyao, Kangmei Pharmaceutical, and Eli Lilly are the major players in the China diabetes therapeutics market.

ID: IN10CNPH036 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Dr. Parul Choudhary

Buy Now

China Diabetes Therapeutics Market Executive Analysis

China's diabetes therapeutics market size is at around $11.56 Bn in 2022 and is projected to reach $27.04 Bn in 2030, exhibiting a CAGR of 11.2% during the forecast period. China is expected to invest $49 Bn in pharmaceutical and biopharma R&D by 2023, growing at a compound annual rate of 23%. By then, 23% of the global total for drug finding and testing will be spent on pharmaceutical and biopharma R&D in China. By 2021, sales of biopharmaceuticals in China are expected to nearly double from their 2016 level to $50 Bn. Before 2030, China's ability to produce world-class medications may be on par with that of the United States and Europe. China's healthcare market was the second-largest in the world in 2018, spending $3.5 trillion in that sector.

It was predicted that between 2020 and 2030, the prevalence of diabetes among Chinese people aged 20 to 79 would rise from 8.2% to 9.7%. The overall costs of diabetes would rise from $250.2 Bn to $460.4 Bn over the same time span or 6.32% annually. First-in-class glucokinase allosteric activator (GKA) with a novel method is HuaTangNing (dorzagliatin tablets). It can be used alone or in conjunction with metformin hydrochloride to enhance blood glucose control for T2D adult patients through diet and exercise (when metformin hydrochloride alone is ineffective in controlling blood glucose). To accomplish one goal with multiple points and coordinated blood glucose control, HuaTangNing aims to restore the damaged glucose sensor glucokinase (GK) in the pancreas, intestine, and liver. It controls the insulin, GLP-1, and glucagon secretion that is triggered by glucose in diabetic patients, which improves early-phase insulin secretion and disposition index. The pancreas, intestine, and liver were found to be the primary target organs in HuaTangNing's research, which showed a linear association between drug dose and plasma exposure. It demonstrated minimal renal excretion and comparable pharmacokinetic profiles in both healthy individuals and patients with end-stage renal disease (ESRD), suggesting that it can be used with ease in patients with renal insufficiency without dose adjustment.

China Diabetes Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

The ageing populace of China is more vulnerable to diabetes and its complications. The rising demand for diabetes treatments as a result of this demographic tendency is anticipated to fuel market expansion. The increase in patients receiving medication treatment, the use of insulin analogues, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-IV) inhibitors, among other drugs, are all contributing to the China diabetes therapeutics market's growth.

Market Restraints

Due to their high costs and lack of reimbursement, doctors currently only prescribe novel anti-diabetics as a last resort when patients are unable to maintain glycemic control with less costly alternatives. The high out-of-pocket expense necessitates patients to be in good financial condition. The China diabetes therapeutics market's potential development is also constrained by Chinese people's preference for traditional medical treatments.

Competitive Landscape

Key Players

Hua Medicine (CHN)
Jiangsu Hansoh Pharmaceutical (CHN)
Walvax Biotechnology (CHN)
Yunnan Baiyao (CHN)
Kangmei Pharmaceutical (CHN)
Eli Lilly
Glaxosmithkline
Novartis
Novo Nordisk
Sanofi
Takeda Pharmaceutical

Notable Deals

October 2022- Hua Medicine claims that the National Medical Products Administration (NMPA) in China has authorized its new drug application (NDA) for HuaTangNing (dorzagliatin tablets). The firm devised HuaTangNing, a first-of-its-kind glucokinase activator (GKA). The approval covers two uses: either as monotherapy for type 2 diabetes (T2D) patients who are drug-naive or in combination with metformin in T2D patients who tolerate metformin to regulate blood glucose levels. In partnership with Bayer, Hua Medicine will market HuaTangNing in China for the advantage of diabetic patients and their families.

Healthcare Policies and Regulatory Landscape

The Chinese regulatory agency that is in charge of overseeing medications, medical equipment, and cosmetics is known as the China Food and Drug Administration (CFDA), or the National Medical Products Administration (NMPA). Among their duties and obligations are the following: routinely evaluating the market's available goods for safety, establishing legislation and rules, encouraging the development of novel technologies, organizing and managing the national essential medicine system, the national essential medicine list, categorization systems, and product standards. Any proposal for a foreign drug must be submitted in Chinese and receive NMPA approval. The drugs' quality, safety, and effectiveness must all be attested to by the manufacturers, who are also responsible for any potential issues. In order to make sure that all the information provided is genuine and accurate, the NMPA will perform inspections at the production site, during non-clinical studies, and during clinical trials. The NMPA is crucial in ensuring the efficacy and safety of medicines and medical goods in China, and its standards and regulations are constantly changing to keep up with changes in the sector.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Therapeutics Segmentation

By Type (Revenue, USD Billion):

Diabetes 1
Diabetes 2

By Application (Revenue, USD Billion):

Preventive
- Prediabetes
- Nutrition
- Obesity
- Lifestyle Management
Treatment/Care
- Diabetes
- Smoking Cessation
- Musculoskeletal Disorders
- Central Nervous System Disorders
- Cardiovascular Disease
- Medication Adherence
- Chronic Respiratory Disorders
- Gastrointestinal Disorders
- Rehabilitation
- Substance Use Disorders & Addiction Management

By Drug (Revenue, USD Billion):

Oral Anti-diabetic Drugs
Insulin
Non-insulin Injectable Drug
Combination Drug

By Route of Administration (Revenue, USD Billion):

Oral
Subcutaneous
Intravenous

By Distribution Channel (Revenue, USD Billion):

Online Pharmacies
Hospital Pharmacies
Retail Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.

We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Yes, I have read the privacy policy

Yunnan Baiyao, Kangmei Pharmaceutical, and Eli Lilly are the major players in the China diabetes therapeutics market.

The China diabetes therapeutics market is expected to grow from $11.56 Bn in 2022 to $27.04 Bn in 2030 with a CAGR of 11.2% for the forecasted year 2022-2030.

The China diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel.